Viatris Inc.

VTRS Healthcare Drug Manufacturers Specialty & Generic

Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024.

Revenue
−0.28%
EPS
−154.6%
Free cash flow
+38.8%
Total debt
−89.4%

Quarter to September 2026, against a year earlier

18.89 0.33 −1.72%
Market cap
$21.8B
P/E
0.0×
Fwd P/E
82.6×
Dividend yield
2.54%
F-score
4/9
Altman Z
0.61
Beneish M
−3.29
Dividend safety
37/100

Viatris Inc. (VTRS) Gross margin

Alert me on Gross margin

Viatris Inc.'s gross margin over the twelve months to 30 September 2026 was 35.3%, up 0.2 percentage points from fiscal 2025 (35.1%). Over the past ten years it has ranged from 31.2% (fiscal 2021) to 44.7% (fiscal 2015); the current reading is higher than 45% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 53.5% and below the Healthcare sector median of 53.9%.

Gross margin, annual

Embed this chart

Annual newest first

Period Gross margin Change (points)
FY2025 35.1% (3.09)
FY2024 38.2% (3.59)
FY2023 41.7% 1.79
FY2022 40.0% 8.78
FY2021 31.2% (0.61)
FY2020 31.8% (2.11)
FY2019 33.9% (1.11)
FY2018 35.0% (5.17)
FY2017 40.2% (2.23)
FY2016 42.4% (2.31)

Quarterly newest first

Period Gross margin Change (points)
Sep 2026 38.4% (0.42)
Jun 2026 38.8% 5.87
Mar 2026 32.9% 1.91
Dec 2025 31.0% (5.49)
43 more quarters

Against its own ten years

Low 31.2% High 44.7%
Ten-year median 38.2%
Current reading's percentile 37

Gross margin against peers

What Gross margin is

Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.

Gross Profit ÷ Revenue

The full definition of Gross margin →

More on VTRS